B BioPulse
Regulatory Sep 09, 2026 · 1 min read · 32,485 views

Gilead gets another HIV treatment approval, extending lenacapavir's dominance

E

Elena Marsh

Editorial · Sep 09, 2026

Gilead gets another HIV treatment approval, extending lenacapavir's dominance

Gilead Sciences' HIV treatment arsenal is getting bigger. The leading drugmaker in the four-decade epidemic gained another FDA stamp of approval on Thursday. This time, Gilead will

Read Original Source Back to Feed

← Previous

Pfizer, Lilly 'most favored nation' deals to give US share of revenue from raised foreign prices

Next →

Nvidia-backed Iambic files for IPO, disclosing new clinic and dealmaking details

Related Reading

Updated: Ultragenyx's new gene therapy will cost $3.95M
Regulatory

Updated: Ultragenyx's new gene therapy will cost $3.95M

Sep 24, 2026

Roivant's road to a potential blockbuster begins with FDA approval for Lisraya
Regulatory

Roivant's road to a potential blockbuster begins with FDA approval for Lisraya

Sep 22, 2026

FDA faces questions on 'America First' provisions in latest user fee agreement
Regulatory

FDA faces questions on 'America First' provisions in latest user fee agreement

Sep 21, 2026